Iroko applies novel delivery platforms and dosing forms to established pharmaceuticals to enhance their therapeutic profiles.

We are focusing on our proprietary SoluMatrix™ nanotechnology platform to reformulate lower-dose NSAIDs, one of the largest-classes of pain-relieving medicines.

We are using the SoluMatrix™ technology to develop lower dosage forms of NSAIDs without compromising the current onset of action or effectiveness of these products This development initiative by Iroko is a direct response to directives issued by the US Food and Drug Administration and the European Medicines Agency that NSAIDs should be used at the lowest effective dose for the shortest possible duration.